CYBERDYNE Online Store



2021-09-13 updated

【News】CYBERDYNE formed a capital and business alliance with Adriakaim, a company that develops a vagus nerve stimulation device

CYBERDYNE Inc. (Tsukuba, Ibaraki, Japan, President & CEO: Yoshiyuki Sankai, referred to as “the Company”) and Adriakaim, Inc. (Hachioji, Tokyo, Representative Director and President: Masatoshi Kobayashi, referred to as “Adriakaim”), a company that develops innovative vagus nerve stimulation device to suppress the onset of chronic heart failure, announced to form a capital and business alliance (CYBERDYNE’s investment in Adriakaim). Furthermore, the Cybernics Excellence Japan Fund 1 Investment Limited Partnership (CEJ Fund), operated by CEJ Capital Inc, will also invest in Adriakaim.

Adriakaim leverages years of research at the National Cardiovascular Center to develop the world’s first vagus nerve stimulation device (ARIS*1). The device can reduce the area of myocardial infarction by stimulating the vagus nerve in patients with acute myocardial infarction. The technology is said to have a higher therapeutic effect on patients with poor prognosis than drugs, as it can realize activation of the vagus nerve through electrical stimulation.

The Company will provide technical, financial, and business support to Adriakaim to contribute to treating many patients with acute myocardial infarction. Through this alliance, the Company sees a possibility of developing the next generation of nerve feedback stimulators by combining the information of electrocardiogram of acute myocardial infarction patients when the Company’s small vital sensor detects extrasystoles, bradycardia, tachycardia, etc. In addition, the Company could also combine its know-how of controlling devices such as Wearable Cyborg HAL, based on bio-electrical signals.

*1 ARIS is a development code, and it may not be the actual name after commercialization

(Comment by CEO Sankai)
Once a person falls into heart failure caused by myocardial infarction, it is difficult to cure it. The condition will significantly reduce activities of daily living (ADL) and Quality of Life (QoL). Adriakaim is taking on the challenge of developing the world’s first innovative medical device to inhibit the onset of heart failure with a vagus nerve stimulation device. The development of this technology is a valuable initiative that will contribute to human health. We will support Adriakaim’s challenge from all angles and coordinate our businesses to innovate the medical field. They can also accelerate their business by using our medical/biotechnology innovation base under construction at Kawasaki Tonomachi King Skyfront, which faces Haneda International Airport. We look forward to your company’s success.

■ Website of Adriakaim:
■ Press release of Adriakaim published on September 13, 2021 (Available in Japanese)